Identity recordInvestigational clinical program
What Pemvidutide resolves to
This is an investigational program, not an approved product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, or regulatory status.
- Evidence lane
- Clinical pipeline profile
- Current record
- Phase 2 programs active; MASH Phase 3 planned
- Checked
- July 18, 2026
ALT-801balanced GLP-1/glucagon dual agonistAltimmune pemvidutide
Destination recordActive QUEST3+ record required
What Malaysia still has to prove
A Malaysia guide to checking peptide-related products in NPRA's QUEST3+ search, matching the MAL registration number, and separating product and supplier licensing claims.
- Comparison mode
- MYR / NPRA product and licensing records
- Price coverage
- No qualified Malaysia seller table
- Guide updated
- July 18, 2026